Brian Cornblatt

Brian Cornblatt, PhD

Chief Medical Officer, BioHarvest Sciences, Advisory Board of Johns Hopkins Colorectal Cancer Center, CSO and Co-Founder of International Nutrition Associates, and Scientific Advisory Board of IntellxxDNA.

Dr. Brian S. Cornblatt is currently the Chief Medical Officer of BioHarvest Sciences, LLC. overseeing product development and supporting company products through the development of translational research initiatives including clinical trials.

Dr. Cornblatt serves as Scientific Advisor for IntellxxDNA and Integration Health Solutions and is an Advisor for the Johns Hopkins Colorectal Cancer Center of Excellence.

Dr. Cornblatt is also the Co-Founder and Chief Scientific Officer of International Nutrition Associates (INA). INA provides clinical trial-backed nutraceuticals to countries throughout Asia and South America as well as novel and high-quality raw materials globally.

Prior to these roles, Dr. Cornblatt was Director, Clinical Research and Science for Nutramax Laboratories Consumer Care, Inc. At Nutramax Laboratories, Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies (28 total clinical trials over a 13-year period) in support of products, summarized both supporting laboratory and clinical research for healthcare workers and consumers, and developed novel IP and patents (3 patents awarded and 4 filed and under review globally).

From 2007-2010 Dr. Cornblatt was the Scientific Director and developer of the Catholic Health Initiatives’ Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI’s 42 Oncology centers and worked with the CHI Oncology Network, a clinical trials group that participated in Phase 1 – Phase IV clinical trials, which Dr. Cornblatt oversaw. Dr. Cornblatt served on the Catholic Health Institutional Review Board (IRB) as well as the Catholic Health Ventures Fund, where he identified and vetted emerging companies for
external investments.

Dr. Cornblatt graduated from the Johns Hopkins University School of Medicine, Ph.D. in Pharmacology and Molecular Sciences, and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.

Dr. Cornblatt has been involved in medical research since 1990. In academia, Dr. Cornblatt oversaw or worked on an additional 8 human clinical trials. Dr. Cornblatt’s main research interests are focused on developing novel formulations comprised of natural based phytochemicals, including isothiocyanates, to minimize chronic inflammation and combat the threats of environmental toxicants. His most recent development has been a novel line of products, Avmacol®, which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Through his efforts, Avmacol
has been used in eighteen supporting human clinical studies globally. Dr. Cornblatt is the inventor of three issued patents and six pending provisional patents focused on plant-based phytochemicals and bioactives and health promotion.

Dr. Cornblatt served on the board of the Susan Cohan Colon Cancer Foundation. His father is a now a 28-year survivor of metastatic colorectal cancer and his mother a survivor of both colon and uterine cancer. Both have had profound influences on his career.

Dr. Cornblatt is the father of two incredible daughters and spends his nights and weekends outdoors as much as possible – either on the soccer and lacrosse fields, running, or cycling in the rural counties of western Maryland.